Table 4 Results of staff questionnaires (n = 13)
Strongly agree | Agree | Neutral | Disagree | Strongly disagree | Not applicable | |
|---|---|---|---|---|---|---|
ADMINISTRATION_A: It was acceptable to give out information to patients in clinic | 4 (31%) | 7 (54%) | 1 (8%) | 1 (8%) | 0 (0%) | 0 (0%) |
ADMINISTRATION_B: There was enough time to collect the additional patient data | 1 (8%) | 3 (23%) | 8 (62%) | 1 (8%) | 0 (0%) | 0 (0%) |
ADMINISTRATION_C: I felt confident collecting the additional patient data | 3 (23%) | 6 (46%) | 4 (31%) | 0 (0%) | 0 (0%) | 0 (0%) |
ADMINISTRATION_D: There was enough time to collect the patient questionnaires | 0 (0%) | 4 (31%) | 5 (38%) | 2 (15%) | 1 (8%) | 1 (8%) |
ADMINISTRATION_E: I felt confident collecting the patient questionnaires | 2 (15%) | 9 (69%) | 2 (15%) | 0 (0%) | 0 (0%) | 0 (0%) |
TRAINING_A: After training I understand how to collect the mouth swab | 7 (54%) | 5 (38%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8%)1 |
TRAINING_B: After training I understand how to transfer cells into the reactor tray using the sample collector | 7 (54%) | 5 (38%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8%)1 |
TRAINING_C: After training I understand how to seal and load the reactive tray into the para-DNA machine | 7 (54%) | 5 (38%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8%)1 |
TRAINING_D: After training I understand how to use the dose calculator programme | 6 (46%) | 6 (46%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8%)1 |
TRAINING_E: After training I felt confident to initiate genotype-guided dosing of warfarin to patients | 6 (46%) | 5 (38%) | 1 (8%) | 0 (0%) | 0 (0%) | 1 (8%)1 |
PROCESS_A: The timing of the genotype-guided dosing system fits in well with the running of the clinic | 1 (8%) | 1 (8%) | 3 (23%) | 6 (46%) | 2 (15%) | 0 (0%) |
PROCESS_B: The patients needed to wait or return to clinic after 50 min to receive their warfarin dose and this fitted in well with the running of the clinic | 0 (0%) | 3 (23%) | 2 (15%) | 5 (38%) | 2 (15%) | 1 (8%) |
PROCESS_C: Patients returned a few days later to have their warfarin dose adjusted and this fitted in well with the running of the clinic | 1 (8%) | 3 (23%) | 3 (23%) | 6 (46%) | 0 (0%) | 0 (0%) |
PROCESS_D: The implementation of genotype-guided dosing for warfarin was worth doing to improve the dosing for patients | 1 (8%) | 2 (15%) | 7 (54%) | 3 (23%) | 0 (0%) | 0 (0%) |
PROCESS_E: Overall the genotype-guided dosing of warfarin appeared to be acceptable to our patients | 0 (0%) | 7 (54%) | 4 (31%) | 2 (15%) | 0 (0%) | 0 (0%) |